Risk for squamous-cell carcinoma (SCC) according to acute and chronic GVHD and duration of immunosuppressive therapy for GVHD
Risk factors . | Case patients, no. . | Control patients, no. . | RR . | 95% CI . | P . |
|---|---|---|---|---|---|
| Model 1: acute, chronic GVHD* | |||||
| No acute, no chronic | 11 | 52 | 1.00 | Reference | - |
| Acute but no chronic | 5 | 22 | 0.91 | 0.29-2.87 | .87 |
| Any chronic GVHD | 42 | 80 | 2.79 | 1.28-6.06 | .01 |
| Chronic but no acute† | 21 | 49 | 2.30 | 0.95-5.57 | .07 |
| Acute and chronic† | 21 | 31 | 3.33 | 1.41-7.87 | .006 |
| Unknown acute or chronic | 0 | 1 | - | - | - |
| Model 2: total duration of immunosuppression prophylaxis, acute and chronic GVHD therapy, mo‡ | |||||
| None, less than 6 | 15 | 51 | 1.00 | Reference | - |
| 6-11 | 6 | 37 | 0.58 | 0.17-1.89 | .36 |
| 12-23 | 11 | 40 | 1.37 | 0.50-3.77 | .54 |
| 24 or greater | 26 | 25 | 5.60 | 2.07-15.19 | <.001 |
| 24-47§ | 11 | 13 | 4.75 | 1.27-17.78 | .02 |
| 48 or greater§ | 15 | 12 | 6.20 | 1.97-19.50 | .002 |
| Unknown | 0 | 2 | - | - | - |
| Model 3: duration of chronic GVHD therapy, mo‡∥ | |||||
| None | 21 | 84 | 1.00 | Reference | - |
| 1-11 | 6 | 26 | 1.00 | 0.35-2.85 | .99 |
| 12-23 | 8 | 27 | 1.37 | 0.50-3.72 | .54 |
| 24 or greater | 23 | 16 | 8.44 | 3.17-22.47 | <.001 |
| 24-47¶ | 10 | 6 | 22.57 | 2.63-193.6 | .005 |
| 48 or greater¶ | 13 | 10 | 6.26 | 2.16-18.16 | <.001 |
| Unknown | 0 | 2 | - | - | - |
Risk factors . | Case patients, no. . | Control patients, no. . | RR . | 95% CI . | P . |
|---|---|---|---|---|---|
| Model 1: acute, chronic GVHD* | |||||
| No acute, no chronic | 11 | 52 | 1.00 | Reference | - |
| Acute but no chronic | 5 | 22 | 0.91 | 0.29-2.87 | .87 |
| Any chronic GVHD | 42 | 80 | 2.79 | 1.28-6.06 | .01 |
| Chronic but no acute† | 21 | 49 | 2.30 | 0.95-5.57 | .07 |
| Acute and chronic† | 21 | 31 | 3.33 | 1.41-7.87 | .006 |
| Unknown acute or chronic | 0 | 1 | - | - | - |
| Model 2: total duration of immunosuppression prophylaxis, acute and chronic GVHD therapy, mo‡ | |||||
| None, less than 6 | 15 | 51 | 1.00 | Reference | - |
| 6-11 | 6 | 37 | 0.58 | 0.17-1.89 | .36 |
| 12-23 | 11 | 40 | 1.37 | 0.50-3.77 | .54 |
| 24 or greater | 26 | 25 | 5.60 | 2.07-15.19 | <.001 |
| 24-47§ | 11 | 13 | 4.75 | 1.27-17.78 | .02 |
| 48 or greater§ | 15 | 12 | 6.20 | 1.97-19.50 | .002 |
| Unknown | 0 | 2 | - | - | - |
| Model 3: duration of chronic GVHD therapy, mo‡∥ | |||||
| None | 21 | 84 | 1.00 | Reference | - |
| 1-11 | 6 | 26 | 1.00 | 0.35-2.85 | .99 |
| 12-23 | 8 | 27 | 1.37 | 0.50-3.72 | .54 |
| 24 or greater | 23 | 16 | 8.44 | 3.17-22.47 | <.001 |
| 24-47¶ | 10 | 6 | 22.57 | 2.63-193.6 | .005 |
| 48 or greater¶ | 13 | 10 | 6.26 | 2.16-18.16 | <.001 |
| Unknown | 0 | 2 | - | - | - |
There were 58 case patients and 155 control patients.
Acute GVHD includes grades 2-4 acute GVHD
Includes the same variables as in the rest of model 1, with the variable any chronic GVHD separated into chronic but no acute and acute and chronic GVHD categories
Total duration (model 2) and duration of chronic GVHD drug therapy (model 3) include months of therapy with immunosuppressive drugs
Model includes the same variables as in model 2, with duration 24 or greater separated into 24-47 and 48 or greater
The reference group of model 3 includes 16 case patients and 74 control patients with no chronic GVHD and 5 case patients and 10 control patients who acquired chronic GVHD that did not require therapy
Model includes the same variables as in model 3, with duration variables 24 or greater separated into 24-47 and 48 or greater